PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Well-being

Drugs in development · updated 30 October 2026

Well-being: drugs in development

As of 30 October 2026 there are 6 active clinical trials (recruiting or ongoing, phases I–III) on 10 drugs for well-being. 2 are experimental, that is not yet approved in the United States.

6Active trials
2Experimental drugs
0Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
PsilocybinPsilocybineII2NCT06233344
MDMA3,4-Methylenedioxymethamphetamine, Midomafetamine HClI1NCT07102576

Sorted by most advanced phase and number of active trials.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
CabotegravirAPRETUDE, Vocabria®II1NCT06411223
RilpivirineEdurant Ped®, Edurant®II1NCT06411223
ClonidineQlonilik®, Javadin®I1NCT07360301
PropofolDiprivanI1NCT06644573
CitalopramCelexa®Early I1NCT06796946
EscitalopramLexaproEarly I1NCT06796946
ParoxetineBrisdelle®, Pexeva®Early I1NCT06796946
SertralineZoloft®Early I1NCT06796946

Sorted by most advanced phase and number of active trials.

All 10 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D000092862 “Psychological Well-Being”.

ItalianoFrançaisDeutsch